Lead Product(s): SCO-101,Taxane
Therapeutic Area: Oncology
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Innovation Fund Denmark
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding February 19, 2020
The grant of DKK 5 million from Innovation Fund Denmark is earmarked for the clinical phase II development of SCO-101 in metastatic pancreatic cancer.